Consequently, treatments that reduce leptin levels, like metformin, thioazolinediones, pioglitazone and statins, which are used to treat metabolic syndrome and insulin resistance, have also demonstrated benefits in downregulating inflammation in EAE and in pwMS with metabolic syndrome [132]. This evidence concerns the gene LEP and metabolic syndrome.